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Summary: Pancreatic acinar cells are critical in gastroin-
testinal physiology and pancreatitis and may be involved
in pancreatic cancer. Previously, a short rat pancreatic
elastase promoter has been widely utilized to control
acinar cell transgene expression. However, this partial
sequence does not confer robust and stable expression.
In this study, we tested the hypothesis that a transgene
employing bacterial-artificial-chromosome (BAC) tech-
nology to express a tamoxifen-regulated Cre recombi-
nase from a full-length mouse elastase gene (BAC-Ela-
CreErT) would be more robust and stable. When found-
ers were crossed with Rosa26 reporter mice nearly
100% of acini expressed b-galactosidase after tamoxi-
fen treatment. The expression was specific for pancre-
atic acinar cells and these characteristics have
remained stable for 2 years. However, because of high
levels of expression in differentiated acinar cells,
this construct is tamoxifen independent in ~50% of adult
acinar cells. This model of pancreatic acinar specific
Cre expression is a powerful tool for future transgenic
and knockout studies. genesis 46:390–395, 2008.
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Pancreatic acinar cells compose nearly 90% of the mass
of the pancreas. These cells are the primary source of di-
gestive enzymes necessary for the breakdown and
absorption of nutrients from food and as such, are neces-
sary for life. Several forms of pathologies also originate
in pancreatic acinar cells. Expression of mutant genes
such as trypsinogen (Whitcomb et al., 1996) or pancre-
atic serine protease inhibitor (Grigorescu and Grigor-
escu, 2005) leads to the development of hereditary
chronic pancreatitis which is a high-risk factor for pan-
creatic cancer (Whitcomb et al., 1999). Furthermore,
recent evidence suggests that pancreatic acinar cells
may undergo metaplasia to form ductal pancreatic ade-
nocarcinoma (Guerra et al., 2007). Thus, manipulation
of gene expression in this cell type will be a valuable
tool for investigations of both physiology and
pathophysiology.
Cell specific manipulation of gene expression is a
powerful tool for the study of the function of certain
genes or for making animal models for a specific disease.
One approach to cell specific gene expression is
achieved using a differentiated cell specific promoter
directly driving gene expression. For directing gene
expression in pancreatic acinar cells the most popular
system was originally developed based on the use of a
short (250–513 bp) rat elastase gene enhancer/promoter
(Rose et al., 1994). This approach has since been used
very widely (Algul et al., 2007; Archer et al., 2006;
Grippo et al., 2003; Guerra et al., 2007; Sandgren et al.,
1990). However, this short genetic element demon-
strates relatively low efficiency (10%–50%). The levels of
expression from this promoter are also relatively low,
although the level of expression can be improved using
flanking regions such as the introns from growth hor-
mone or metallothionine (Palmiter et al., 1991). How-
ever, even with these additional elements expression
from this small elastase element is far less robust than
expression from the endogenous gene (Quaife et al.,
1987). Furthermore, this promoter is susceptible to
unstable expression and infrequently may be lost in a
few generations.
Another disadvantage of directly using the elastase
promoter is that transgene expression from a differenti-
ated cell specific gene promoter of this sort is likely to
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be greatly diminished if the expressed gene influences
the differentiated state of the cells. A much more versa-
tile approach is to use the Cre-loxP strategy to activate
experimental gene expression from a constitutive pro-
moter (Branda and Dymecki, 2004). For tissue specific
gene expression using this system, a flanking loxP-stop-
loxP cassette is added between a constitutive promoter
and the experimental gene of interest (a so-called flox-
stopped gene). The loxP-stop-loxP cassette prevents the
experimental gene from being expressed until it is
removed by Cre-recombinase. If the Cre-recombinase is
expressed by a cell-specific promoter, then expression
of the experimental gene takes place in a cell-specific
manner even though the promoter driving gene expres-
sion is not cell-type specific. If the promoter used to
drive the experimental transgene is not influenced by
the state of cellular differentiation, then the experimen-
tal transgenes will continue being expressed even if the
cells change phenotype. Another advantage of this sys-
tem is that it can be combined with multiple flox-
stopped-genes that exist in the scientific community, en-
abling economical use of available genetically modified
models. This system can also be utilized for specific
gene ablation when genes or relevant exons have been
flanked by loxP sites allowing for cell-type specific dele-
tion based on the expression of Cre recombinase.
A modification of Cre-recombinase that allows regu-
lated activity has also been developed and has proven
valuable in numerous studies (Guo et al., 2002). This
Cre is modified by fusion to estrogen receptor elements
that can bind the artificial estrogen, tamoxifen (CreErT).
Under control conditions, in the absence of tamoxifen,
CreErT binds to HSP90 which prevents the molecule
from entering the nucleus and blocks its recombinase
function. However, addition of tamoxifen releases the
CreErT from HSP90 and allows movement to the nucleus
where the CreErT is active. Several recent models have
been developed using the short rat elastase enhancer/
promoter to drive CreErT expression (Desai et al., 2007;
Murtaugh et al., 2005; Strobel et al., 2007). The expres-
sion of CreErT from these models is highly specific but
not highly efficient, with 10%–50% of the cells showing
tamoxifen induced expression. In models with higher
efficiency some tamoxifen-independent expression is
also noted (Murtaugh et al., 2005). However, in general
these are excellent models for acinar specificity and
tamoxifen inducibility so long as high efficiency is
not necessary. Unfortunately, high efficiency is often
desirable, particularly when investigating the effects of
Cre-mediated gene deletion.
To develop an improved system for pancreatic acinar
cell specific transgene expression, we tested the hypoth-
esis that a full-length pancreatic elastase gene construct
developed using bacterial artificial chromosome (BAC)
technology (Copeland et al., 2001) would prove supe-
rior to the short elastase promoter. The BAC, with the
intact mouse elastase gene, contains all the regulatory
components for elastase expression and the native sur-
rounding gene locus which protects the transgene from
being influenced by other local genes that may occur
during random genomic insertion. This was predicted to
allow high efficiency and specificity for genes expressed
by this promoter.
For comparing the efficiency of Cre-recombination,
we developed mouse models in which a tamoxifen-
inducible Cre-recombinase was expressed by either the
commonly utilized short rat elastase enhancer (Ela-
CreErT) or a full-length mouse pancreatic elastase I gene
promoter (BAC-Ela-CreErT) (Figs. 1a and 2a). Seven Ela-
CreErT founders and two BAC-Ela-CreErT founders were
identified by genotyping. Q-PCR based analysis indicated
the presence of 10–15 copies of the transgene in Ela-
CreErT founders and 2–3 copies in BAC-Ela-CreErT
founders. To detect Cre recombination activity, these
mice were crossed with Rosa26 reporter mice which
carry a flox-stopped b-galactosidase gene. Double trans-
genic mice or single transgene littermates were injected
daily with tamoxifen (3 mg/40 g body weight) for 3
days. The mice were sacrificed at 5 days and the pan-
creata were removed for X-gal staining. We found only
one out of seven Ela-CreErT lines (1/7) showed b-galac-
tosidase activity. This line displayed only 10%–15% X-gal
positive cells in the pancreas when crossed with Rosa26
mice (Fig. 1b). In contrast, double transgenic mice devel-
oped from both BAC-Ela-CreErT founders crossed with
Rosa26 displayed X-gal staining in nearly 100% of pancre-
atic acinar cells after tamoxifen treatment (Fig. 2b).
These data indicate a major difference in efficiency for
the full-length elastase gene compared with the short
promoter.
Consistent with the known distribution of endoge-
nous elastase expression, X-gal staining in BAC-Ela-
CreErT 3 Rosa26 double transgenic mice was exclu-
sively localized to pancreatic acinar cells and not in duct
or endocrine islets cells (Fig. 2b). Similar specificity was
FIG. 1. Gene expression driven by a short rat elastase enhancer
was not efficient. (a) CreErT gene was inserted between a 500 bp
rat elastase enhancer and human growth hormone polyA signal. (b)
Transgenic founders were crossed with Rosa26 reporter mice. Dou-
ble transgenic mice were injected with tamoxifen at 3 mg/40 g body
weight daily for 3 days and sections of the pancreata were stained
with X-gal. Approximately 10–15% of acini were labeled in a mosaic
pattern.
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noted with the Ela-CreErT 3 Rosa26 mice (data not
shown). An attempt was made to analyze expression of
these constructs in centroacinar cells. A few centroaci-
nar cells could be identified and these did not show X-
gal staining (Fig. 2c). Similarly, immunofluorescent local-
ization of CreErT and Hes-1, a marker for centroacinar
cells, did not show colocalization (Fig. 2d). However,
because of the difficulty of localizing centroacinar cells
it was not possible to rule out the expression of CreErT
in this cell type. Nonetheless, these data clearly indicate
that the BAC transgene is at least as specific as the short
elastase enhancer.
During the investigation of Cre activation in the ani-
mals crossed with Rosa26 it was noted that some acinar
cells expressed b-galactosidase in the absence of tamoxi-
fen treatments (Fig. 3). To understand this tamoxifen in-
dependent Cre-activity, we investigated b-galactosidase
expression in animals of different ages. We observed
that in the absence of tamoxifen no expression of b-ga-
lactosidase was observed in developing mice at 19.5
days post-coitus in the absence of tamoxifen treatment
(Fig. 3a). Treatment of pregnant mice with tamoxifen (1
mg/day for 3 days) resulted in widespread activation of
b-galactosidase in the pancreas of same aged embryos
indicating the presence of the CreErT transgene at this
early time (Fig. 3b). At day 1, after birth 1% of cells
showed activated b-galactosidase in the absence of
tamoxifen (Fig. 3c). The percentage of labeled cells
increased over-time (Fig. 3d–3f) with a dramatic increase
after weaning (between day 14 and 29) such that 50%
of adult cells were labeled in the absence of tamoxifen
(Fig. 3f). The spontaneous CreErT activity was only
observed in easily recognizable acinar cells (Fig. 3c
insert). This increase in Cre activity paralleled the nor-
mal increase in elastase gene expression that occurs in
mice during this period, as during weaning there is
known to be a spike in elastase expression (Han et al.,
1986). Levels of CreErT paralleled those of endogenous
elastase in this mouse model (Fig. 3j). Thus, the most
likely explanation for this phenomenon is that CreErT is
expressed at very high levels in the pancreas when
driven from the full-length elastase gene. Indeed, we
found that the CreErT expression in the BAC transgene
was even higher than that of a CAGGS-CreErT transgene
(Fig. 3j) which utilizes a CMV-chicken beta actin chi-
meric promoter to drive CreErT expression (Hayashi and
McMahon, 2002). In adults, the spontaneous level of
Cre-activity occurred in roughly 40%–50% of the acinar
cells (Fig. 3g). Treatment with tamoxifen was able to
induce the other 50%–60% of acinar cells (Fig. 3h,i).
To examine the stability of the CreErT expression in
the transgenic models, we examined the efficiency of
b-galactosidase expression in the animals again after
2 years of breeding (eight generations). We found that
the BAC transgene maintained expression in 100%
of pancreatic acinar cells when treated with tamoxifen
(Fig. 3h). In contrast, the animals with the short elastase
promoter lost nearly all CreErT expression (Data not
shown).
In summary, we have shown that a full-length elastase
gene in a BAC provides for highly efficient and stable
development of pancreatic acinar directed transgene
expression. Using this system, a new transgenic mouse
line has been developed that expresses CreErT in pan-
FIG. 2. CreErT expression from a
full length elastase gene promoter
was highly efficient and specific.
(a) CreErT gene was targeted
between the last exon and polyA
signal of the mouse elastase I
gene in a bacterial artificial chro-
mosome. (b). Founders were
crossed with Rosa26 mice,
injected with tamoxifen and stained
with X-gal. Nearly 100% of acini
were stained with no staining in
ducts, islets, or blood vessels. (c)
X-gal staining was negative in a
centroacinar cell. (d). CreErT (red)
was not colocalized with Hes1
(green), a centroacinar marker.
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creatic acinar cells. This model is highly efficient, spe-
cific, and stable. The high levels of CreErT expression
achieved in adult acinar cells allow for some tamoxifen-
independent expression. However, tamoxifen adminis-
tration is still able to induce rapid induction of gene
expression in the remaining acinar cells. This model will




All mouse colonies were maintained in a specific
pathogen-free barrier facility at the University of Michi-
gan and the University of Texas M. D. Anderson Cancer
Center approved by the Association for Assessment and
Accreditation of Laboratory Animal Care International,
and procedures conformed to the Institutional Animal
Care and Use Committee protocols. CAGGS-CreErT mice
were provided by Dr. Andrew P. McMahon (Harvard
Medical School, Boston, MA).
Construction of Ela-CreErT
CreErT was released from pBS with Apa I and EcorRI,
blunt ligated to a 531bp rat elastase promoter (a gift
from Dr. Raymond MacDonald, UT Southwestern Univer-
sity, Dallas, TX) containing a human growth hormone
poly A sequence. The Ela-CreErT-polyA cassette was
released and used for producing transgene.
Construction of BAC-Ela-CreErT
A mouse BAC (clone RP23-359O19, size 222 kb) carry-
ing the intact elastase I gene was used. Alignment
according to the BAC end sequencing with sp6 and T7
primer, this BAC is localized between 100,425,585 and
100,648,109 on chromosome 15. The BAC was modified
to express CreErT with an E. coli-based chromosome en-
gineering system developed by Dr. Copeland (NCI)
(Copeland et al., 2001). pIGCN-Cre-ErT was produced
FIG. 3. BAC-Ela-CreErT mice
developed tamoxifen independ-
ence in acinar cells with high
expression levels. Pancreas from
a BAC-Ela-CreErT 3 Rosa26 em-
bryo at 19.5 days post-coitus
(dpc) was X-gal negative (a). Injec-
tion of pregnant mice with tamoxi-
fen (3 daily injections with 1 mg/40
g) generated many X-gal positive
cells in embryos removed at 19.5
dpc (b). In the absence of tamoxi-
fen, the number of X-gal positive
cells increased with age. Data
shown are without tamoxifen on
day 1 (c), day 7 (d), day 14 (e), day
29 (f), and day 60 (g) after birth.
Injection of tamoxifen in animals
after 8 weeks (three daily injec-
tions with 3 mg/40 g) led to the
expected x-gal staining in nearly
100% of acini (h). Unstained cells
are either islets (arrowhead) or
ducts (arrow). Sections were
counterstained with fast red. All
were photographed at 3100 mag-
nification. Quantitation of X-gal
staining at the different times indi-
cated the time-course of leakage
of BAC-Ela-CreErT (i). The expres-
sion level of CreErT paralleled the
level of endogenous elastase ex-
pression as indicated by Western
blot (j).
393ROBUST ACINAR CELL TRANSGENE EXPRESSION OF CreErT
by replacing the EGFP-Cre with Cre-ErT (provided by Dr.
Andrew P. McMahon, Harvard Medical School, Boston,
MA) in plasmid pICGN21. For recombination mediated
targeting, arms homologous to the sequence of elastase I
gene between the last exon and the polyA signal (in
lower case) were added to either side of the IRES-Cre-




Using homologous recombination, the IRES-Cre-ErT-frt-
Kan-frt cassette was inserted into the elastase I gene.
The Kan selection marker was then removed by flp-
mediated recombination and the insertion site and orien-
tation were verified by sequencing.
Generation Of Transgenic Mice
The subcloned DNA were purified and transgenic
mice (Ela-CreErT) were developed at the University of
Michigan Transgenic Animal Model Core by pronuclear
microinjection. The BAC-Ela-CreErT mice were pro-
duced through the University of Texas M. D. Anderson
Cancer Center Genetically Engineered Mouse Facility.
Genotyping
Tail biopsies were performed at 3 weeks of age. DNA
was prepared for PCR with REDExtract-N-AmpTM Tissue
PCR Kit (Sigma, St. Louis, MO) according to manufac-
ture’s protocol. Primers (Forward: gcctgcattaccggtcga,
Reverse: tatcctggcagcgatcgc) were used to detect the
Cre gene. Transgene copy numbers were determined
by Q-PCR using beta globin (Forward: ccaatctgctcacacag
gatagagagggcagg, Reverse ccttgaggctgtccaagtgattcaggc
catcg) as a standard.
b-Galactosidase Reporter Assay
To determine the temporal and spatial expression pro-
files of the CreErT transgenes, we crossed the CreErT
transgenic mice with Rosa26 reporter mice. The re-
porter mice express b-galactosidase in the presence of
active Cre recombinase (Soriano, 1999). After three daily
injections of tamoxifen 3 mg per 40 g body weight, the
pancreas was embedded in OCT and sectioned for X-gal
staining. Sections were postfixed with 0.25% glutaralde-
hyde in PBS and briefly washed with rinse solution (0.1
M phosphate buffer, pH 7.3, 0.1% deoxycholic acid,
0.2% NP-40, and 2 mM MgCl2). X-gal staining was per-
formed by incubating samples in staining buffer (2.5
mg/ml X-gal, 5 mM potassium ferricyanide, and 5 mM
potassium ferrocyanide) overnight at 378C and in some
cases followed by counterstaining with nuclear fast red.
Immunofluorescence
Frozen sections of the pancreas 8 lm thick were fixed
in freshly prepared 4% paraformaldehyde for 30 min.
The sections were then permeablized with 0.5% Triton
X-100 for 30 min and blocked with 5% bovine serum al-
bumin in phosphate-buffered saline containing 0.05%
Triton X100. Polyclonal antibodies against Cre (1:1,000,
EMD Chemicals, Gibbstown, NJ) and Hes1 (1:50, Santa
Cruz Biotechnology, Santa Cruz, CA) were added over-
night at 48C before Alexa Fluor 594 donkey anti-rabbit
IgG and Alexa Fluor 488 labeled donkey anti-goat IgG
secondary antibodies were applied (Vector Laboratories,
Burlingame, CA). Fluorescent imaging was taken on a
Zeiss LSM510 confocal scanning microscope (Zeiss,
Thornwood, NY).
Western Blotting
Western blotting was performed as previously
described with modification (Ji et al., 2001). Briefly, pan-
creata were harvested and homogenized in lysis buffer
(50 mM/l HEPES, pH 7.5, 150 mM/l NaCl, 2.5 mM/l
EGTA, 0.1% Tween-20, 1 mM/l dithiothreitol, 1 mM/l,
NaF, 0.1 mM/l sodium orthovanadate, 0.1 mM/l phenyl-
methylsulfonyl fluoride, 2 lg/ml aprotinin, and 5 lg/ml
leupeptin) and centrifuged to remove cellular debris.
Samples of 30 lg of protein denatured with Laemmli
buffer were subjected to electrophoresis on sodium do-
decyl sulfate-polyacrylamide gels and transferred by elec-
troblotting to Hybond membranes. The blots were incu-
bated with primary antibodies anti-Cre (1:10,000, EMD
Chemicals Inc. Gibbstown, NJ) and anti-elastase (Abcam,
Cambridge, MA). Fluorescent dye labeled secondary anti-
body was used for detection with Odyssey Infrared Imag-
ing System (LI-COR Biotechnology, Lincoln, Nebraska).
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